Ghost Tree Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Ghost Tree Capital’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,750,000	Closed	-$3.67M	–	61
2018 Q1	$3.67M	Buy	+1,750,000	New	+$3.75M	0.74%	41
2014 Q3	–	Sell	-75,000	Closed	-$956K	–	86
2014 Q2	$956K	Buy	+75,000	New	+$781K	0.67%	45

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ghost Tree Capital's INFI Position: Q2 2018 in Review

Ghost Tree Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2018, closing a stake of 1,750,000 shares — an estimated $3.67M sold.

Ghost Tree Capital first reported a position in INFI in Q2 2014 and held it in 2 quarters. The position peaked at $3.67M in Q1 2018. 64 funds tracked by Wall St. Rank hold INFI as of Q2 2018.

Ghost Tree Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Ghost Tree Capital sold 1,750,000 Infinity Pharmaceuticals, Inc. shares in Q2 2018, an estimated $3.67M.
Ghost Tree Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
Ghost Tree Capital's Infinity Pharmaceuticals, Inc. position peaked at $3.67M in Q1 2018.
64 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2018.

Based on Ghost Tree Capital's 13F filing for Q2 2018, filed 14 Aug 2018.